Cabaletta Bio Q2 2024 GAAP EPS $(0.56) Misses $(0.55) Estimate, Cash, Cash Equivalents And Short-term Investments Total $203.2M As Of June 30, 2024, Expected To Support Operations Into The First Half Of 2026
Author: Benzinga Newsdesk | August 08, 2024 08:30am